HANSOH PHARMA's Investigational ADC for Small Cell Lung Cancer Wins NMPA Filing Acceptance

Stock News

昨天

HANSOH PHARMA (03692) has announced that its investigational new drug, HS-20093 for injection, has had its marketing authorization application accepted for review by China's National Medical Products Administration (NMPA) on September 2, 2026.

The application covers the use of this innovative therapy in adult patients with small cell lung cancer (SCLC) whose disease has progressed following prior platinum-based treatment.

HS-20093 for injection is a B7-H3-targeting antibody-drug conjugate (ADC) developed independently by the company's research team.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1123460749"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123460749\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123460749?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123460749","market":"us","top_or_hot":-1,"title":"HANSOH PHARMA's Investigational ADC for Small Cell Lung Cancer Wins NMPA Filing Acceptance","media":"Stock News","content":"<p><b>HANSOH PHARMA</b> (03692) has announced that its investigational new drug, HS-20093 for injection, has had its marketing authorization application accepted for review by China's National Medical Products Administration (NMPA) on September 2, 2026.<br><br>The application covers the use of this innovative therapy in adult patients with small cell lung cancer (SCLC) whose disease has progressed following prior platinum-based treatment.<br><br>HS-20093 for injection is a B7-H3-targeting antibody-drug conjugate (ADC) developed independently by the company's research team.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA's Investigational ADC for Small Cell Lung Cancer Wins NMPA Filing Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA's Investigational ADC for Small Cell Lung Cancer Wins NMPA Filing Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-02 16:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HANSOH PHARMA</b> (03692) has announced that its investigational new drug, HS-20093 for injection, has had its marketing authorization application accepted for review by China's National Medical Products Administration (NMPA) on September 2, 2026.<br><br>The application covers the use of this innovative therapy in adult patients with small cell lung cancer (SCLC) whose disease has progressed following prior platinum-based treatment.<br><br>HS-20093 for injection is a B7-H3-targeting antibody-drug conjugate (ADC) developed independently by the company's research team.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1123460749","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123460749","pubTimestamp":1788338175,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HANSOH PHARMA (03692) has announced that its investigational new drug, HS-20093 for injection, has had its marketing authorization application accepted for review by China's National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药","IPOS":"Renaissance International IPO ETF","BK1583":"高瓴概念","BK1589":"北水核心资产","BK1191":"制药"},"translate_title":"豪森制药小细胞肺癌在研ADC获NMPA备案受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1,"IPOS":1},"content_text":"HANSOH PHARMA (03692) has announced that its investigational new drug, HS-20093 for injection, has had its marketing authorization application accepted for review by China's National Medical Products Administration (NMPA) on September 2, 2026.The application covers the use of this innovative therapy in adult patients with small cell lung cancer (SCLC) whose disease has progressed following prior platinum-based treatment.HS-20093 for injection is a B7-H3-targeting antibody-drug conjugate (ADC) developed independently by the company's research team.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}